Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) comments on the Hot Line trial, EXPLORER-HCM. The trial measured the efficacy and safety of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.

Recorded remotely from Milan, 2020. 

Recording Editor: Natascha Wienand
Editor: Mirjam Boros